Background
The World Health Organization (WHO) estimates that acute respiratory infections (ARI) cause annual deaths approaching 4 million, at a rate of more than 60 deaths/100,000 populations [
1]. Viruses are responsible for 30-70 % of ARI where respiratory syncytial virus (RSV), influenza virus, parainfluenza virus (PIV), human Bocavirus, human metapneumovirus (hMPV), adenovirus, rhinovirus, enterovirus and Coronaviruses account for the majority of these cases [
1,
2]. The 2009 influenza pandemic had highlighted the need for more global data on severe influenza disease, so the WHO recommended conducting surveillance for hospitalized severe acute respiratory infection (SARI), as well as influenza-like illness (ILI) in outpatients [
3‐
6]. SARI surveillances are now conducted in many countries around the world; however, because of limited resources, they are only conducted in limited settings in the Middle East and Egypt [
7‐
9]. Furthermore, the role of individual viral or atypical bacterial infection in causing ARI is not usually documented [
10,
11].
In the current study, we analyzed surveillance data from Egyptian patients with SARI, enrolled at Cairo University Hospital (CUH) from 2010 to 2014. We aimed to calculate proportions of positive samples for different viral pathogens, to determine which pathogens were related to severe outcomes, and to address the impact of SARI on the clinical outcomes of enrolled patients, in terms of morbidity and mortality.
Results
Demographic data of the study population
Out of 3,207 participants enrolled in this SARI surveillance, 1,075 (33.5%) had positive results for viral and atypical bacteria tested. They included 569/1,075 (53%) females and 506/1,075 (47%) males. The median age was one year (range 0-85 years). Children less than 18 years had a higher viral etiology (981 patients, 91.2%) compared to 94 (8.8%) ones in adults. Notably, children <5 years represented 83% of patients. The highest rates of viral infections were reported for RSV (485 patients, 45.2%), PIV (125, 11.6%), and adenovirus (105, 9.8%). Other encountered viruses included rhinovirus, hMPV, and BOCA virus (2%,7%, and 1%, respectively). Only 3 cases were positive for Mycoplasma and were co-infected with RSV, while only one case of Chlamydia was co-infected with RSV and hMPV. Neither Coronavirus nor Legionella was detected. Table
1 shows these data.
Table 1
Demographic and clinical characteristics of patients hospitalized with severe acute respiratory infection (SARI) cases in Egypt, 2010–2014
Demographics |
Gender |
Female | 810 (38) | 569 (53) | 0.562 | 257 (53) | 1.000 | 90 (52) | 0.741 | 65 (52) | 0.449 | 47 (45) | 0.081 | 48 (62) | 0.054 |
Male | 1,322 (62) | 506 (47) | | 228 (47) | | 84 (48) | | 60 (48) | | 58 (55) | | 29 (38) | |
Age in years |
Mean ± SD | 16.96 ± 25.3 | 5.74 ± 13.8 | | 3.15 ± 9.64 | | 5.48 ± 12.55 | | 6.48 ± 14.82 | | 4.48 ± 11.12 | | 19.52 ± 23.47 | |
Median | 1.0 | 1.0 | | 0.67 | | 1.0 | | 1.0 | | 1.0 | | 5.0 | |
(Range) | (0–90) | (0–85) | | (0–85) | | (0–77) | | (0–74) | | (0–57) | | (0–76) | |
< 18 years | 1,493 (70) | 981 (91) | 0.000 | 470 (97) | 0.000 | 162 (93) | 0.143 | 111 (89) | 0.523 | 97 (92) | 0.330 | 47 (61) | 0.000 |
< 1 year | 831 | 501 | | 269 | | 73 | | 59 | | 29 | | 23 | |
1–5 years | 567 | 384 | | 165 | | 66 | | 46 | | 52 | | 17 | |
> 5 years | 95 | 96 | | 36 | | 23 | | 6 | | 16 | | 7 | |
> 18 years | 639 (30) | 94 (9) | | 15 (3) | | 12 (7) | | 14 (11) | | 8 (8) | | 30 (39) | |
Signs & symptoms at presentation |
Shortness of breath | 1,555 (73) | 1,033 (96) | 0.000 | 485 (100) | NA | 174 (100) | NA | 125 (100) | NA | 105 (100) | NA | 77 (100) | NA |
Sore throat | 654 (31) | 273 (25) | 0.001 | 174 (36) | 0.001 | 35 (20) | 0.087 | 33 (26) | 0.429 | 18 (17) | 0.024 | 18 (23) | 0.394 |
Sputum production | 1,169 (55) | 566 (53) | 0.077 | 254 (52) | 0.902 | 86 (49) | 0.396 | 66 (53) | 0.524 | 63 (60) | 0.068 | 46 (60) | 0.120 |
Hemoptysis | 62 (3) | 20 (2) | 0.047 | 5 (1) | 0.110 | 4 (2) | 0.869 | 3 (2) | 0.426 | 2 (2) | 0.599 | 3 (4) | 0.175 |
Body aches | 153 (7) | 165 (15) | 0.000 | 60 (12) | 0.005 | 30 (17) | 0.490 | 26 (21) | 0.060 | 22 (21) | 0.065 | 10 (13) | 0.391 |
Tachypnea | 1,732 (81) | 1,000 (93) | 0.000 | 442 (91) | 0.362 | 154 (88) | 0.292 | 108 (86) | 0.459 | 98 (93) | 0.084 | 74 (96) | 0.038 |
Nasal congestion | 300 (14) | 647 (60) | 0.000 | 322 (66) | 0.161 | 113 (65) | 0.244 | 69 (55) | 0.128 | 53 (50) | 0.397 | 30 (39) | 0.131 |
Wheezing | 360 (17) | 881 (82) | 0.000 | 414 (85) | 0.186 | 141 (81) | 0.342 | 108 (86) | 0.123 | 82 (78) | 0.455 | 42 (55) | 0.000 |
Stridor | 22 (1) | 7 (0.6) | 0.127 | 3 (0.6) | 1.000 | 0 (0) | 0.606 | 1 (0) | 0.586 | 1 (0) | 0.514 | 2 (0) | 0.052 |
Abnormal Breath Sounds | 955 (45) | 558 (52) | 0.159 | 239 (49) | 0.140 | 84 (48) | 0.314 | 74 (59) | 0.054 | 60 (57) | 0..256 | 49 (64) | 0.023 |
Nausea or vomiting | 209 (10) | 116 (11) | 0.360 | 54 (11) | 1.000 | 29 (17) | 0.011 | 12 (10) | 0.349 | 8 (7) | 0.174 | 5 (6) | 0.401 |
Convulsions | 63 (3) | 108 (10) | 0.000 | 44 (9) | 0.245 | 18 (10) | 0.891 | 15 (12) | 0.284 | 17 (16) | 0.026 | 8 (10) | 0.215 |
Comorbidities |
Chronic Resp disease | 343 (16) | 460 (43) | 0.002 | 227 (47) | 0.062 | 52 (30) | 0.044 | 35 (28) | 0.066 | 45 (43) | 0.078 | 35 (45) | 0.053 |
Asthma | 87 | 119 | | 77 | | 22 | | 21 | | 28 | | 26 | |
COPD | 42 | 66 | | 13 | | 6 | | 2 | | 0 | | 4 | |
Bronchiectasis | 101 | 133 | | 88 | | 11 | | 9 | | 12 | | 2 | |
Othersa | 113 | 142 | | 49 | | 13 | | 3 | | 5 | | 3 | |
Cardiac disease | 512 (24) | 214 (20) | 0.392 | 81 (17) | 0.046 | 37 (21) | 0.050 | 31 (25) | 0.078 | 26 (25) | 0.055 | 12 (16) | 0.158 |
Heart failure | 299 | 44 | | 22 | | 13 | | 14 | | 9 | | 7 | |
Congenital HD | 114 | 147 | | 48 | | 15 | | 11 | | 15 | | 2 | |
Cardiomyopathy | 99 | 23 | | 11 | | 9 | | 6 | | 2 | | 3 | |
Endocrine disease | 147 (7) | 124 (12) | 0.000 | 50 (10) | 0.249 | 19 (11) | 0.897 | 24 (19) | 0.004 | 13 (12) | 0.420 | 12 (16) | 0.158 |
Diabetes mellitus | 100 | 106 | | 37 | | 12 | | 21 | | 11 | | 11 | |
Obesity | 47 | 18 | | 13 | | 7 | | 3 | | 2 | | 1 | |
Neuromuscular disease | 176 (8) | 90 (8) | 0.001 | 30 (6) | 0.033 | 15 (9) | 0.063 | 19 (15) | 0.012 | 10 (10) | 0.398 | 6 (8) | 0.233 |
Muscle dis | 123 | 37 | | 13 | | 11 | | 12 | | 6 | | 4 | |
Epilepsy | 53 | 53 | | 17 | | 4 | | 7 | | 4 | | 2 | |
Renal disease | 43 (2) | 11 (1) | 0.951 | 5 (1) | 0.866 | 0 (0) | 0.322 | 3 (2) | 0.198 | 0 (0) | 0.314 | 2 (3) | 0.200 |
Chronic RF | 34 | 9 | | 5 | | | | 3 | | | | 2 | |
Nephrotic Syndrome | 9 | 2 | | 0 | | | | 0 | | | | 0 | |
Hepatic disease | 54 (3) | 9 (1) | 0.002 | 2 (0.5) | 0.001 | 3 (2) | 0.192 | 2 (2) | 0.277 | 1 (1) | 0.579 | 1 (1) | 0.496 |
Ch hepatitis | 9 | 5 | | 2 | | 2 | | 0 | | 1 | | 1 | |
Liver cirrhosis | 33 | 3 | | 0 | | 1 | | 2 | | 0 | | 0 | |
Hepatic failure | 12 | 1 | | 0 | | 0 | | 0 | | 0 | | 0 | |
Hematologic disease | 23 (1) | 5 (0.5) | 0.583 | 0 (0) | 0.051 | 1 (0.5) | 0.428 | 1 (1) | 0.377 | 2 (2) | 0.079 | 1 (1) | 0.496 |
Clinical course |
Pneumonia | 175 (8) | 29 (3) | 0.004 | 13 (2.6) | 0.033 | 4 (2) | 0.066 | 1 (1) | 0.288 | 4 (4) | 0.054 | 3 (4) | 0.299 |
Admission to ICU | 606 (28) | 219 (20) | 0.000 | 82 (17) | 0.022 | 41 (23) | 0.123 | 20 (16) | 0.007 | 22 (21) | 0.064 | 36 (47) | 0.045 |
Mechanical ventilation | 221 (10) | 100 (9) | 0.412 | 43 (9) | 0.052 | 13 (7) | 0.778 | 8 (6) | 0.373 | 7 (7) | 0.213 | 17 (22) | 0.001 |
Complications |
Respiratory failure | 45 (2) | 22 (2) | 0.033 | 9 (2) | 0.552 | 4 (2) | 0.488 | 2 (2) | 0.607 | 4 (4) | 0.101 | 1 (1) | 0.349 |
ARDS | 3 (0.1) | 15 (1.5) | 0.011 | 8 (2) | 0.063 | 4 (2) | 0.072 | 0 (0) | 0.237 | 0 (0) | 0.064 | 0 (0) | 0.078 |
Outcomes$ |
Discharged | 1,852 (87) | 956 (89) | 0.005 | 433 (89) | 0.045 | 153 (88) | 0.051 | 116 (93) | 0.289 | 100 (95) | 0.131 | 62 (81) | 0.006 |
Transferred | 174 (8) | 95 (8.8) | | 40 (8.6) | | 20 (11.5) | | 7 (6) | | 3 (3) | | 10 (13) | |
Died | 106 (5) | 24 (2.2) | | 12 (2.4) | | 4 (2) | | 1 (1) | | 2 (2) | | 4 (5) | |
Clinical characteristics of viral-infected versus no virus-detected individuals
In comparison to non-viral infected individuals, viral-infected SARI ones had significantly predominant signs and symptoms at presentation. Particularly, they had significant viral prodromal symptoms, as well as tachypnea, wheezes, and convulsions (p=0.000 each). Among individual viral pathogens, SARI patients with influenza had more significant tachypnea (p= 0.038), wheezes (p=0.000), and abnormal breath sounds (p= 0.023), than those with non-influenza viral infections. Patients whose specimens were collected within 5 days of the onset of symptoms were more likely to have a viral pathogen detected than those whose specimens were collected later (73% versus 36%, p = 0.047).
Fifty-three percent of patients had at least one underlying medical condition. These comorbidities included chronic respiratory disorders (asthma, COPD, bronchiectasis, and immotile cilia syndrome), cardiac disorders (heart failure congenital heart diseases, and cardiomyopathy), neuromuscular disorders (epilepsy, cerebral palsy, and myopathies), hematological disorders (thalassemia), endocrine disorders (diabetes mellitus, hypothyroidism, and morbid obesity), renal disorders (end-stage renal disease), and liver disorders (liver cirrhosis and hepatic failure).
Patients with comorbidities (n = 570, 53%) were significantly older compared to those with no comorbidities (median age: 54 versus 3, p <0.001). Additionally, they were significantly more likely to be symptomatic.
In terms of comorbidities, patients with and without viral detection differed significantly in the frequencies of chronic respiratory (p=0.002), endocrine (p=0.000), hepatic (p=0.002), and neuromuscular disorders (p=0.001). Among individual viral pathogens, SARI patients with para-influenza virus had significant endocrine (p= 0.004), and neuromuscular disorders (p=0.012), than those with non-para-influenza viral infections.
For influenza vaccination history; 832/1,075 (77.4%) cases did not receive the vaccine within the 12 months prior to hospital admission, while 243/1,075 (22.6%) were reported as unknown for an influenza vaccination status. Table
1 details these results.
Clinical course, complications, and outcomes in viral-infected patients
In comparison to non-viral infected individuals, viral-infected SARI ones had significantly lower rates of pneumonia (p=0.004) and admission to the ICU (p=0.000). Patients with influenza virus tended to have significantly different rates of admission to the ICU (p=0.045), and mechanical ventilation (p=0.001), in comparison to those with non-influenza infections. With regards to complications, viral-infected SARI patients had significant differences for developing respiratory failure (p=0.033), and acute respiratory distress syndrome; ARDS (p=0.011), in comparison to those without viral infections.
Overall mortality in SARI-positive patients was 24/1,075 (2.2%) and peaked at 1% in 2014. Overall, only 2(8%) were adults, while 22 (92%) were children. Among children, 18(75%) were aged <5 years. Overall, two-thirds (16/24) had comorbidities. All patients who died were admitted to the ICU and mechanically ventilated. Notably, all patients who died tested positive for a viral pathogen; twelve were positive for RSV, four for influenza virus, two for adenovirus, one for hMPV, one for PIV and four for mixed viral infections, respectively. Among those who died, there was a significant difference between those with (2.2%) and without (5%) viral detection (
p = 0.005). Among individual viral pathogens, SARI patients with RSV and influenza had significant deaths (p= 0.045 and 0.006), in comparison to those with non-RSV and non-influenza viral infections. No mortality was reported for patients with atypical bacteria (Table
1).
Severe outcomes in viral-infected patients
No infections were independently associated with increased severity of SARI, as indicated by illness requiring mechanical ventilation and/or ICU and/or resulting in death. There was strong evidence that individuals with RSV and influenza were less likely to experience a severe outcome than those not infected with each of these pathogens (RSV OR 1.433, 95% CI 4.698-6.132. p=0.021, influenza OR 3.937, 95% CI 2.447-6.3340, p=0.000). Individuals with multiple infections were no more likely than those with infection with a single pathogen to experience severe outcomes (OR 0.232, 95% CI 0.155-0.619, p = 0.240).
When analyses were stratified by age, neither significant differences in severe outcomes could be encountered between viral-infected and non-infected individuals (OR 0.983, 95% CI 0.503-1.924, p=0.961 and OR 1.100, 95% CI 0.704-1.718, p=0.675) nor between individual viral infections, among children and adults. Table
2 shows these details (Data for PIV, hMPV, Boca virus, rhino-, and enterovirus are not shown in the table).
Table 2
Indicators of the severity of SARI by pathogen and age
All participants |
Ventilation | 100/ 1,075 (9) | 1.280 (0.703- 2.329 | 0.419 | 43/485 (9) | 0.177 (−1.005- 0.185) | 0.866 | 7/105 (7) | 1.293 (0.682- 2.452) | 0.431 | 17/77 (22) | 3.123 (1.743- 5.598) | 0.000 | 13/174 (7) | 0.755 (0.412- 1.386) | 0.365 |
ICU | 219/ 1,075 (20) | 0.972 (0.706- 1.337) | 0.861 | 82/485 (17) | 1.897 (12.591- 13.635) | 0.017 | 22/105 (21) | 1.040 (0.634- 1.707) | 0.876 | 36/77 (47) | 3.910 (2.431- 6.290) | 0.000 | 41/174 (23) | 0.225 (0.162- 0.612) | 0.254 |
Death | 24/ 1,075 (2) | 0.00 (0.941- 0.966) | 0.557 | 12/485 (2) | 0.530 (−1.215- 0.625) | 0.637 | 2/105 (2) | 0.837 (0.194- 3.609) | 0.811 | 4/77 (5) | 0.986 (−0.114- 2.085) | 0.079 | 4/174 (2) | 0.036 (1.050- 1.122) | 0.948 |
Severe Outcome | 219/ 1,075 (20) | 0.972 (0.706- 1.337) | 0.861 | 82/485 (17) | 1.433 (4.698- 6.132) | 0.021 | 22/105 (21) | 1.047 (0.638- 1.738) | 0.857 | 36/77 (47) | 3.937 (2.447- 6.334) | 0.000 | 41/174 (23) | 0.232 (0.155- 0.619) | 0.240 |
Children <18 years |
Ventilation | 66/ 981 (7) | 1.032 (0.305- 3.541) | 0.952 | 36/485 (8) | 0.894 (0.566- 1.413) | 0.632 | 7/105 (7) | 0.907 (04.05- 2.032) | 0.812 | 5/77 (6) | 1.785 (0.676- 4.713) | .0243 | 13/174 (7) | 0.995 (0.536- 1.849) | 0.988 |
ICU | 178/ 981 (18) | 0.983 (0.503- 1.924) | 0.961 | 68/485 (14) | 0.838 (0.594- 1.182) | 0.314 | 11/105 (10) | 0.691 (0359- 1.330) | 0.268 | 10/77 (13) | 2.008 (0.952- (4.237) | 0.067 | 32/174 (18) | 1.418 (0.921- 2.185) | 0.113 |
Death | 13/ 981 (1) | 0.973 (0.960- (0.987) | 0.784 | 12/485 (2) | 1.363 (0.583- 1.385) | 0.474 | 2/105 (2) | 0.966 (0.222- 4.198) | 0.963 | 2/77 (2) | 2.640 (0.594- 11.740) | 0.202 | 4/174 (2) | 1.162 (0.338- 3.479) | 0.789 |
Severe Outcome | 178/ 981 (18) | 0.983 (0.503- 1.924) | 0.961 | 68/485 (14) | 0.849 (0.602- 1.199) | 0.353 | 11/105 (10) | 0.697 (0.362- 1.342) | 0279 | 10/77 (13) | 2.024 (0.959- 4.271) | 0.064 | 32/174 (18) | 1.432 (0929- 2.206) | 0.114 |
Adults >18 years |
Ventilation | 34/94 (36) | 1.357 (0.645- 2.856) | 0.421 | 7/485 (1) | 0.966 (0.114- 2.085) | 0.078 | 0/105 (0) | 2.991 (0.851- 10.514) | 0.088 | 12/77 (16) | 2.878 (1014- 8.166) | 0.052 | 0/174 (0) | 0.787 (0.669- 0.885) | 0.063 |
ICU | 41/94 (44) | 1.100 (0.704- 1.718) | 0.675 | 14/485 (3) | 1.493 (0.282- 2.452) | 0.527 | 11/105 (10) | 3.235 (0.671- 15.593) | 0.143 | 26/77 (34) | 0.929 (0.392- 2.198) | 0.866 | 9/174 (5) | 0.606 (0.203- 1.815) | 0.371 |
Death | 11/94 (12) | 0.934 (0.912- 0.965) | 0.793 | 0/485 (0) | 0.848 (0.437- 1.196) | 0.691 | 11/105 (10) | 0.859 (0.790- 0.933) | 0.645 | 2/77 (2) | 0.413 (0.324- 0.527) | 0.351 | 0 (0) | 0.826 (0.752- 0.907) | 0.763 |
Severe Outcome | 41/94 (44) | 1.100 (0.704- 1.718) | 0.675 | 14/485 (3) | 1.493 (0.282- 2.452) | 0.527 | 0/105 (0) | 3.235 (0.671- 15.593) | 0.143 | 26/77 (34) | 0.929 (0.392- 2.198) | 0.866 | 9/174 (5) | 0.606 (0.203- 1.815) | 0.371 |
Logistic regression was used to further examine associations with severe outcomes in SARI-positive individuals with complete demographic data and clinical risk factors. By univariate analysis, individuals with positive results for rhinovirus and adults >18 years were more likely to experience a severe outcome than those not infected with rhinovirus (OR 4.975, 95% CI 2.431-17.812, p=0.024) and children <18 years (OR 10.357, 95% CI 5.895-18.197, p=0.000), respectively.
Multivariate analysis confirmed these results where individuals with positive results for rhinovirus and adults >18 years were more likely to experience a severe outcome than those not infected with rhinovirus (OR 4.807, 95% CI 2.981-16.112, p=0.025) and children <18 years (OR 11.716, 95% CI 7.225-18.998, p=0.000), respectively.
Table
3 shows these results.
Table 3
Univariate and multivariate logistic regression for predictors of severe outcomes among viral-infected SARI cases
Univariate Analysis |
| | OR (95% CI) | P |
RSV | Negative | ref |
Positive | 0.00 (−) | 0.989 |
Adenovirus | Negative | ref |
Positive | 0.927 (0.533–1.612) | 0.788 |
Rhinovirus | Negative | ref |
Positive | 4.975 (2.431–17.812) | 0.024 |
Enterovirus | Negative | ref |
Positive | 0.00 (−) | 1.000 |
Influenza | Negative | ref |
Positive | 1.150(0.608–2.176) | 0.667 |
BOCA virus | Negative | ref |
Positive | 0.413 (0.051–3.371) | 0.409 |
HMPV | Negative | ref |
Positive | 0.845 (0.431–1.656) | 0.624 |
PIV | Negative | ref |
Positive | 0.633 (0.361–1.112) | 0.112 |
Multiple viruses | Single virus | ref |
Multiple viruses | 1.515 (0.974–2.357) | 0.065 |
Age | Adults >18 years | ref |
Children <18 years | 10.357 (5.895–18.197) | 0.000 |
Gender | Male | ref |
Female | 0.893 (0.643–1.239) | 0.497 |
Comorbidities | None | ref |
Any | 1.181 (0.840–1.661) | 0.338 |
Multivariate analysis |
| | OR (95% CI) | P value |
Rhinovirus | Negative | ref |
Positive | 4.807 (2.981–16.112) | 0.025 |
Age | Adults >18 years | ref |
Children <18 years | 11.716 (7.225–18.998) | 0.000 |
Comparison between RSV-positive and other viral cases
Being the most commonly detected virus among our cohort, clinical characteristics and outcomes of RSV-positive patients were compared to those with other respiratory positive cases as well as viral-negative patients.
While patients with RSV-positive infections had significant differences with those with no respiratory viruses identified, with regards to clinical signs and symptoms, comorbidities, and outcomes (ICU admission and deaths); they had no differences with those tested positive for other viral pathogens, with regards to the same parameters. (Table
4 shows these details)
Table 4
Comparison of SARI patients with RSV to those with a non-RSV or to those with no respiratory virus identified
Gender |
Female | 257 (53) | 312 (53) | 0.203 | 810 (38) | 0.000 |
Male | 228 (47) | 278 (47) | | 1,322 (62) | |
Age |
Below 18 y | 470 (97) | 511 (87) | 0.801 | 1,493 (70) | 0.373 |
Above 18 y | 15 (3) | 79 (13) | | 639 (30) | |
Symptom onset ≤7 days | 456 (94) | 480 (81) | 0.064 | 1,211 (57) | 0.250 |
Cough | 485 (100) | 536 (91) | 0.882 | 2,132 (100) | 1.000 |
SOB | 485 (100) | 548 (93) | 1.000 | 1,555 (73) | 0.077 |
Fever | 485 (100) | 590 (100) | 1.000 | 2,132 (100) | 1.000 |
Sore throat | 174 (36) | 311 (53) | 0.000 | 654 (31) | 0.000 |
Sputum production | 254 (52) | 312 (53) | 1.000 | 1,169 (55) | 0.870 |
Body aches | 60 (12) | 105 (18) | 0.063 | 153 (7) | 0.004 |
Tachypnea | 442 (91) | 558 (95) | 0.063 | 1,732 (81) | 0.087 |
Nasal congestion | 322 (66) | 325 (55) | 1.000 | 300 (14) | 0.060 |
Wheezing | 414 (85) | 467 (79) | 0.031 | 360 (17) | 0.063 |
Abnormal BS | 239 (49) | 319 (54) | 0.008 | 955 (45) | 0.022 |
Nausea or vomiting | 54 (11) | 62 (10) | 0.988 | 209 (10) | 0.003 |
Convulsions | 44 (10) | 64 (11) | 0.677 | 63 (3) | 0.046 |
pneumonia | 13 (3) | 16 (3) | 1.000 | 175 (8) | 0.001 |
Chronic lung disease | 227 (47) | 233 (39) | 0.086 | 343 (16) | 0.001 |
Cardiac disease | 81 (17) | 133 (23) | 0.063 | 512 (24) | 0.022 |
Endocrine disease | 50 (10) | 74 (13) | 0.866 | 147 (7) | 0.002 |
Renal disease | 5 (1) | 6 (1) | 1.000 | 43 (2) | 0.246 |
Neuromuscular disorder | 30 (6) | 60 (10) | 0.333 | 176 (8) | 0.033 |
ICU | 82 (17) | 137 (23) | 0.121 | 606 (28) | 0.000 |
Ventilation | 43 (9) | 57 (10) | 0.473 | 221 (10) | 0.343 |
ARDS | 8 (1) | 7 (1) | 1.000 | 3 (0) | 0.000 |
Respiratory Failure | 9 (2) | 13 (2) | 0.988 | 45 (2) | 1.000 |
Death | 12 (2) | 12 (2) | 1.000 | 106 (5) | 0.000 |
Severe outcomes in RSV-positive patients
Logistic regression was used to examine associations with severe outcomes in RSV-positive patients with complete demographic data and clinical risk factors. By univariate analysis, individuals with RSV and associated comorbidities were more likely to experience severe outcomes (OR 4.703, 95% CI 0.803-9.672, p=0.001) than those with RSV and no comorbidities (Table
5).
Table 5
Logistic regression for predictors of severe outcomes for RSV-positive cases
| | OR (95% CI) | P |
Gender | Male | ref |
Female | 1.600 (0.400–6.163) | 0.086 |
Age | Adults >18 years | ref |
Children <18 years | 1.119 (0.276–4.466) | 0.151 |
Comorbidities | None | ref |
Any | 4.703(0.803–9.672) | 0.001 |
Discussion
To the best of our knowledge, this is the largest surveillance Egyptian study that addressed the epidemiological patterns of SARI due to viruses and atypical bacteria in both children and adult population and their relation to the clinical characteristics and outcomes of those patients.
The worldwide distribution of viral etiology as a cause of SARI varies between 2% and up to 78% [
7,
11,
13,
14]. In this study, we found a viral etiology in 33.5 % of hospitalized patients with SARI, which is comparable to previous studies conducted in either developing or Middle Eastern countries [
9‐
11,
13]. The finding that two-thirds of SARI cases had no pathogen detected suggests that poor or late specimen collection may have contributed to a lower yield of detected viruses. Interestingly, children <18 years represented the majority (91.2%) of our cohort. Notably, this contradicts findings observed by other studies [
14,
15]. In their surveillance for SARI in Northern Vietnam, Nguyen
et al [
15] observed that 22.7% of their cohort were children <18 years, while 77.3% were adults >18 years. Again, children <5 years represented 83% of our cases. This is in accordance with those surveillance data from Southern Arizona, 82% [
14], lower than those from China (94% in <72 months) [
16] and higher than in Kenya,71% [
11].
The highest rates of viral infections were reported for RSV (45.2%), PIV (11.6%), and adenovirus (9.8%), with a relatively low rate (7.2%) for influenza viruses. Not unexpected, RSV was the most predominant respiratory virus with a prevalence of 45%; emphasizing its role as the major cause of SARI in infants and young children worldwide [
7,
8,
13‐
17]. Notably, the proportion of SARI cases positive for RSV in children <5 years in our surveillance (90%) was markedly higher than those reported in surveillance data from Kenya, 21% [
11], Southern Arizona, 31% [
14], and even higher than previous studies in Egypt [
18].
We observed that, SARI cases <5 years were significantly more likely than older patients to be infected with each of the pathogens examined, particularly for RSV and influenza. As the majority of enrolled patients were children (83%), this is not unexpected since these pathogens have a strong association with this age group. This is inconsistent with data that nearly 80% of children are exposed to RSV by age two, 100% to hMPV by age five and 90% to hPIV by age five [
19]. Furthermore, hPIV is a significant etiology of LRTI in children [
20], second only to RSV [
21], and adenoviruses are the second most common viral pathogen in children under two years of age [
7].
Notably, our results showed a very minor role for atypical bacteria in causing SARI in our locality. Only 3 cases were positive for Mycoplasma (co-infected with RSV), while only one case of Chlamydia was co-infected with RSV and hMPV. Clinical presentations differed significantly between those with non-viral infected individuals and viral-infected SARI ones. The later had significant viral prodromal symptoms, as well as tachypnea, wheezes, and convulsions. Furthermore, SARI patients with influenza had significant tachypnea, wheezes, and abnormal breath sounds, than those with non-influenza viral infections. The presence of these signs at presentation could help the clinician predicting the likely pathogen causing SARI [
14].
Fifty-three percent of our patients had medical comorbidities, with the predominance of chronic lung diseases (43%). The impacts of medical comorbidities on patients with SARI were addressed in previous surveillance studies [
9,
13,
14]. Despite that 83% of our cohort were children less than 5 years, and patients with comorbidities were significantly older compared to those with no comorbidities, patients with and without viral detection differed significantly in the frequencies of chronic respiratory, as well as endocrine, hepatic and neuromuscular disorders.
Comparing the clinical course, complications, and outcomes between viral-infected cases and non-viral detected controls showed interesting results. Patients with identified viruses had significantly lower rates for ICU admission, hospital stay, length of mechanical ventilation, and overall mortality than those without identified viruses. However, there were no differences with regards to ARDS and mechanical ventilation.
Previous studies showed conflicting results on the impacts of viral infections on clinical outcomes in patients with SARI [
9,
13,
14,
19,
22,
23]. Differences in patients’ numbers, enrollment criteria, and methodologies could explain these results. Although PCR has been established as a reliable diagnostic assay with high sensitivity and specificity for respiratory viruses, particularly for RSV [
24], the clinical implications of positive laboratory results are still less clear [
13].
Patients with positive viral detection had better clinical outcomes than those with no viral detection, in terms of pneumonia, ICU admission, and overall mortality. Furthermore, compared to patients with no virus identified, patients with RSV-positive infection were significantly less likely to have pneumonia, to be admitted to the ICU, mechanically ventilated, and had less mortality.
Interestingly, analyses to assess associations with severe outcomes in the current study revealed that no infections were independently associated with those outcomes, even after controlling for age and associated medical comorbidities. Despite the predominance of RSV infections among SARI-positive cases (45%), there was strong evidence that individuals with RSV and influenza were less likely to experience a severe outcome than those not infected with each of these pathogens. Furthermore, individuals with multiple infections were no more likely than those with infection with a single pathogen to experience severe outcomes.
Multivariate logistic regression analysis confirmed that individuals with positive results for rhinovirus and adults >18 years were more likely to experience a severe outcome than those not infected with rhinovirus and children <18 years, respectively. However, because of the low prevalence of rhinovirus (2%) and adults (8.8%) in this study, further larger studies are needed to confirm these associations.
Being the most commonly detected virus among our cohort, there was an interest to examine the RSV-positive cases. Interestingly, while patients with RSV-positive infections had significant differences with those with no respiratory viruses identified with regards to clinical signs and symptoms, comorbidities, and outcomes; they had no differences with those tested positive for other viral pathogens with regards to the same parameters.
However, individuals with RSV and associated medical comorbidities were more likely to experience severe outcomes than those with RSV and no comorbidities, after controlling for age and other risk factors.
Again, review of the literature had shown conflicting results for clinical implications of RSV infection [
9,
23‐
28]. While the relationship between RSV infection and clinical disease has been established, as infections among asymptomatic individuals are rare [
9,
24‐
27], no relationship between viral load and disease severity was identified by others [
23,
28,
29]. For non-influenza viruses, the clinical features are still unclear. Adenovirus infection levels in asymptomatic children and adults varied [
27,
30], though this may be attributable to differences in sampling methodology since throat swabs may detect latent AdV DNA in tonsil tissue [
27]. Studies suggest that asymptomatic infection with hMPV is rare among children [
31], but results from adult populations are less conclusive, with reports of varying levels of infection among asymptomatic individuals [
25,
32].
Furthermore, the clinical implications of positive laboratory results are further complicated by the presence of co-infections. Multiple viral respiratory pathogens were identified in 16.7% of our cases. Co-infection with 2 or more viral respiratory pathogens has been encountered in previous reports among pediatric populations in the Middle East [
13,
18,
33,
34]. Multiple infections complicate diagnosis, as the relative clinical impact of each pathogen is unclear [
13], and certain pathogens, such as adenovirus, are routinely found in the upper airways [
35].
This study has many points of strength; it was the first surveillance that addresses the clinical impacts and epidemiological patterns of viral and atypical bacteria causing SARI in both children and adult Egyptian population, with enrolled large numbers of patients and over a relatively long period. Furthermore, analyses of homogenous populations, rather than different ethnic groups [
14], give the results reliable and strong support. On the other hand, it has some limitations; more time may be needed for properly evaluating the role of atypical bacteria, and the flu vaccine was not used.